Literature DB >> 26130512

Personalized medicine in adult acute lymphoblastic leukemia.

Dieter Hoelzer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26130512      PMCID： PMC4486219          DOI： 10.3324/haematol.2015.127837

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  26 in total

1.  Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Robin Foà; Antonella Vitale; Marco Vignetti; Giovanna Meloni; Anna Guarini; Maria Stefania De Propris; Loredana Elia; Francesca Paoloni; Paola Fazi; Giuseppe Cimino; Francesco Nobile; Felicetto Ferrara; Carlo Castagnola; Simona Sica; Pietro Leoni; Eliana Zuffa; Claudio Fozza; Mario Luppi; Anna Candoni; Ilaria Iacobucci; Simona Soverini; Franco Mandelli; Giovanni Martinelli; Michele Baccarani
Journal:  Blood       Date:  2011-09-19       Impact factor: 22.113

Review 2.  Novel antibody-based therapies for acute lymphoblastic leukemia.

Authors:  Dieter Hoelzer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 3.  Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis.

Authors:  Ron Ram; Ofir Wolach; Liat Vidal; Anat Gafter-Gvili; Ofer Shpilberg; Pia Raanani
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

4.  Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

Authors:  Renato Bassan; Orietta Spinelli; Elena Oldani; Tamara Intermesoli; Manuela Tosi; Barbara Peruta; Giuseppe Rossi; Erika Borlenghi; Enrico M Pogliani; Elisabetta Terruzzi; Pietro Fabris; Vincenzo Cassibba; Giorgio Lambertenghi-Deliliers; Agostino Cortelezzi; Alberto Bosi; Giacomo Gianfaldoni; Fabio Ciceri; Massimo Bernardi; Andrea Gallamini; Daniele Mattei; Eros Di Bona; Claudio Romani; Anna Maria Scattolin; Tiziano Barbui; Alessandro Rambaldi
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

Review 5.  Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

Authors:  M Brüggemann; A Schrauder; T Raff; H Pfeifer; M Dworzak; O G Ottmann; V Asnafi; A Baruchel; R Bassan; Y Benoit; A Biondi; H Cavé; H Dombret; A K Fielding; R Foà; N Gökbuget; A H Goldstone; N Goulden; G Henze; D Hoelzer; G E Janka-Schaub; E A Macintyre; R Pieters; A Rambaldi; J-M Ribera; K Schmiegelow; O Spinelli; J Stary; A von Stackelberg; M Kneba; M Schrappe; J J M van Dongen
Journal:  Leukemia       Date:  2009-12-24       Impact factor: 11.528

Review 6.  Modern therapy of acute lymphoblastic leukemia.

Authors:  Renato Bassan; Dieter Hoelzer
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

7.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

8.  Minimal residual disease in acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

9.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

Authors:  Hagop Kantarjian; Deborah Thomas; Jeffrey Jorgensen; Elias Jabbour; Partow Kebriaei; Michael Rytting; Sergernne York; Farhad Ravandi; Monica Kwari; Stefan Faderl; Mary Beth Rios; Jorge Cortes; Luis Fayad; Robert Tarnai; Sa A Wang; Richard Champlin; Anjali Advani; Susan O'Brien
Journal:  Lancet Oncol       Date:  2012-02-21       Impact factor: 41.316

10.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316
View more
  8 in total

Review 1.  Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.

Authors:  Monika Brüggemann; Michaela Kotrova
Journal:  Blood Adv       Date:  2017-11-28

Review 2.  Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.

Authors:  Monika Brüggemann; Michaela Kotrova
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia.

Authors:  Ashwini Kumar; Matti Kankainen; Alun Parsons; Olli Kallioniemi; Pirkko Mattila; Caroline A Heckman
Journal:  BMC Genomics       Date:  2017-08-17       Impact factor: 3.969

Review 4.  Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.

Authors:  Irene Della Starza; Sabina Chiaretti; Maria S De Propris; Loredana Elia; Marzia Cavalli; Lucia A De Novi; Roberta Soscia; Monica Messina; Antonella Vitale; Anna Guarini; Robin Foà
Journal:  Front Oncol       Date:  2019-08-07       Impact factor: 6.244

5.  Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.

Authors:  Andrea Ghelli Luserna Di Rorà; Neil Beeharry; Enrica Imbrogno; Anna Ferrari; Valentina Robustelli; Simona Righi; Elena Sabattini; Maria Vittoria Verga Falzacappa; Chiara Ronchini; Nicoletta Testoni; Carmen Baldazzi; Cristina Papayannidis; Maria Chiara Abbenante; Giovanni Marconi; Stefania Paolini; Sarah Parisi; Chiara Sartor; Maria Chiara Fontana; Serena De Matteis; Ilaria Iacobucci; Pier Giuseppe Pelicci; Michele Cavo; Timothy J Yen; Giovanni Martinelli
Journal:  J Hematol Oncol       Date:  2018-08-01       Impact factor: 17.388

6.  A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia.

Authors:  Renato Bassan; Monika Brüggemann; Hoi-Shen Radcliffe; Elizabeth Hartfield; Georg Kreuzbauer; Sally Wetten
Journal:  Haematologica       Date:  2019-03-19       Impact factor: 9.941

7.  Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study.

Authors:  Renato Bassan; Dieter Hoelzer; Xavier Thomas; Pau Montesinos; Jiri Pavlu; Jan McKendrick; Amber Kudlac; Arie Barlev; Beth Barber; Ze Cong
Journal:  Adv Ther       Date:  2019-03-07       Impact factor: 3.845

Review 8.  Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.

Authors:  Caroline Le Jeune; Xavier Thomas
Journal:  Drug Des Devel Ther       Date:  2016-02-18       Impact factor: 4.162
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.